EGFR and head and neck squamous cell carcinoma: Cetuximab, an anti-EGFR monoclonal antibody (mAb), was the first FDA-approved molecular-targeted drug for the treatment of HNSCC [33] and has been approved as a first-line treatment for relapsed and/or metastatic HNSCC.